You are here

Our science / Clinical Trials / Find a Trial / NCT01692899

Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

Back to Search Print Save as PDF Bookmark Trial

NCT01692899

Last updated on December 5, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- RA defined by the 1987 ACR criteria [18]

- first TNFα inhibitor prescribed in the previously mentioned period

- TNFα inhibitor prescribed as first-line biotherapy

- undergone at least one evaluation in the center after treatment initiation

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- previously received another biotherapy

- TNF? inhibitor was prescribed in an RCT

- refused to participate

NCT01692899
Pfizer
Completed
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
NCT02674386
All Genders
18+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
NCT02709486
All Genders
18+
Years
Multiple Sites
Juvenile Idiopathic Arthritis
Efficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
All Genders
2+
Years
Multiple Sites
Rheumatoid Arthritis
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
NCT02831855
All Genders
18+
Years
Multiple Sites
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line tumor necrosis factor ? inhibitors (TNFi).
In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done after adjustment using a Cox model. Factors associated with better retention were identified by multivariate analysis. Medical charts of all patients with RA starting a first TNF? inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France) and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in detail by 2 rheumatologist investigators
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
RA defined by the 1987 ACR criteria [18]; first TNF? inhibitor prescribed in the previously mentioned period; TNF? inhibitor prescribed as first-line biotherapy; and patients had undergone at least one evaluation in the center after treatment initiation. Patients were excluded if: they had previously received another biotherapy; the TNF? inhibitor was prescribed in an RCT; or they refused to participate.
Rheumatoid Arthritis
Not Provided
  • Etanercept
    Etanercept: administered as first line biotherapy in RA during the period of the study
  • Adalimumab
    Adalimumab: administered as first line biotherpy in RA during the period of the study
  • Infliximab
    Infliximab: administered as first line biotherpy in RA during the period of the study
Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine. 2014 Jul;81(4):352-9. doi: 10.1016/j.jbspin.2014.02.014. Epub 2014 Apr 8.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
780
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • RA defined by the 1987 ACR criteria [18]
  • first TNF? inhibitor prescribed in the previously mentioned period
  • TNF? inhibitor prescribed as first-line biotherapy
  • undergone at least one evaluation in the center after treatment initiation

Exclusion Criteria:

  • previously received another biotherapy
  • TNF? inhibitor was prescribed in an RCT
  • refused to participate
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01692899
NRB1800007
B1801356
No
Not Provided
Not Provided
Pfizer
Pfizer
scientific steering committee of KOL in rheumatology
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2012

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now